New Job Opportunity

Nurse Capital Launches Exclusive Network for Nurse Entrepreneurs

Nurse Capital, a venture capital fund that invests in early-stage healthcare startups founded and led by nurses, is proud to announce the launch of the Nurse Capital Network (NCN), an exclusive, invitation-only community designed to connect and empower nurse entrepreneurs and inventors. NCN will foster information sharing, networking with funders and industry experts, and creative collaboration that cultivates entrepreneurial innovations in products and services that transform the nursing care ecosystem. "Nurse Capital is committed to providing a space where nurse-led ventures can thrive," said Nurse Capital Co-founder Beth A. Brooks, Ph.D., RN, FACHE. "The Nurse Capital Network is more than just a resource for funding. Nurse entrepreneurs often find their career path lonely due to the unique challenges of balancing business responsibilities with their healthcare expertise." Membership in the Nurse Capital Network is by invitation only to nurse entrepreneurs committed to advancing healthcare innovation. Key features of the Nurse Capital Network include: Networking Opportunities: Members can connect with General Partners, Limited Partners, and other members to build meaningful relationships. Mentorship & Peer Learning: Opportunities for both mentoring and being mentored by seasoned industry leaders and fellow entrepreneurs. Educational Sessions: Expert-led discussions and workshops designed to enhance members' skills, knowledge, and understanding of industry challenges. Access to Resources: Exclusive access to funding opportunities, business tools, and insights to support members' entrepreneurial journeys. "We created Nurse Capital Network to provide support to ensure that the businesses of nurse entrepreneurs have the greatest impact on advancing nursing and healthcare innovation," said Nurse Capital Co-founder Maura Weston, Ph.D., RN, FAAN.

Jubilant Ingrevia Commissions New cGMP Facility in Gujarat for Nutraceuticals

Jubilant Ingrevia Limited announced the commissioning of its new cGMP compliant facility at Bharuch, Gujarat. The new facility will manufacture Nutraceuticals and Dietary-Active ingredients for human consumption. The facility is an extension of the company’s USFDA approved plant that is already supplying to the U.S., Europe, Japan and many other markets. It will be fully equipped to cater to the needs of the biggest marquee customers in the nutrition and cosmetics space.Customers seeking greener supply chains and high bio-content in their inputs, will especially stand to benefit. The Niacinamide from the new plant in addition to its various applications in skin and hair care, will also pave way for the Company to foray into infant nutrition market globally, with food grade Niacin. The production of these new grades of Vitamin B3 will significantly enhance the Company's presence within value-added products with this high-value and high-margin offering. Speaking on the development, Mr. Deepak Jain, CEO & Managing Director, Jubilant Ingrevia Limited said, “The commissioning of our new facility for Niacinamide aimed at nutrition and cosmetic applications is an important milestone in our journey. We are already one of the world's largest producers of Niacinamide and as we ramp up the utilisation of this new plant, we aim to become global leader in Vitamin B3 in the coming years. With this, we are now among a select few capable of producing high-quality Vitamin B3 for these high-value, high margin offerings. It also gives us a strategic moat, protecting us from industry volatility in feed-gradeNiacinamide

Solvias Unveils Biologics & Cell Therapy Hub, bringing 200 new jobs

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced the opening of its cutting-edge Center of Excellence for Biologics and Cell and Gene Therapy in the heart of Research Triangle Park (RTP), North Carolina. The new facility expands Solvias' global network of centers and reinforces its commitment to advancing transformative therapies for cancer and rare diseases. Spanning 50,000 square feet, the new center is Solvias' flagship North American site for large molecule analytical services designed to accelerate the development and commercialization of innovative biologics. The facility will bring approximately 200 new jobs to the Raleigh-Durham area over the next three years and is being rolled out in two phases: Phase 1: A 20,000-square-foot space for cGMP release testing—featuring cell-based potency and molecular assays—operational immediately. Phase 2: An additional 30,000 square feet expected to open in July 2025, offering expanded capabilities for stability testing and advanced biophysical characterization. Equipped with state-of-the art analytical instrumentation, laboratory automation, and advanced digital management systems, the new center offers comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biologics, from preclinical stages to commercial release. "This Center of Excellence in RTP is a milestone in Solvias' global growth journey," said Archie Cullen, Chief Executive Officer of Solvias. "Combining our team's expertise with advanced technology, we aim to set a new benchmark for delivering high-quality, reliable analytical support. It's an honor to partner with our clients in bringing groundbreaking therapies to patients worldwide." "We are focused on helping our clients succeed with our analytical expertise. We are hiring the best possible talent to be technical partners for our clients, helping them bring therapies to market faster and more efficiently. With this investment, we are committed to be an integral part of the US biopharma innovation ecosystem," said Ilya Koltover, Chief Commercial Officer of Solvias. Solvias' new center expands its global footprint to six centers of excellence and marks the company's second site in North America

Sartorius and McMaster University Open New Bioprocessing Automation Lab

The life science group Sartorius and McMaster University today opened a new bioprocessing automation lab at the university’s Faculty of Engineering in Hamilton, Ontario. The state-of-the-art, 1,600-square-foot research facility was created complementing a substantial contribution of advanced biomanufacturing equipment from Sartorius, a long-standing partner of the university. The lab will serve as a training and development hub, where McMaster students and Sartorius employees work with other industry partners to accelerate developments in bioprocess modelling, simulation, and advanced control. “The opening of the Sartorius Bioprocess Automation Lab marks a milestone in McMaster’s commitment to advancing biomanufacturing capabilities in Canada,” says Dr. Heather Sheardown, Dean of the Faculty of Engineering at McMaster University. “This generous contribution will support technological innovations in large-scale biotherapeutics manufacturing that enhance production efficiency and ultimately expand access to life-saving treatments for chronic illnesses such as autoimmune disorders and cancers.” Prof. Dr. Oscar-Werner Reif, Chief Technology Officer of Sartorius, adds, “This partnership enables McMaster University and Sartorius to explore and industrialize innovative bioprocessing solutions together with partners from the biopharmaceutical industry. In this state-of-the-art facility young researchers from academia and the industry will jointly develop innovative modelling and predictive control solutions that help to simplify and accelerate biomanufacturing processes – ultimately driving faster developments of improved therapies that will be accessible to patients around the world.” The funding for the new facility comes via stage two of the Biosciences Research Infrastructure Fund (BRIF) competition, the centerpiece of a $2.2 billion CAD national program developed to build a strong and resilient domestic biomanufacturing and life sciences sector. This makes it the first BRIF-funded facility to open in Canada. “In the crucial biomanufacturing field, the opening of this lab will help Canadian researchers secure the competitive advantage they need to maintain the prosperity, health and security of our country,” said Dr. Sylvain Charbonneau, President and CEO of the Canada Foundation for Innovation. “With public and private sector support, this cutting-edge facility will help prepare the new generation of innovators.” Building on these contributions, a team of McMaster researchers has secured additional Alliance Grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to launch an extensive four-year collaboration with Sartorius. Dr. David Latulippe, associate professor of chemical engineering and co-director of the Biointerfaces Institute at McMaster University, and the principal investigator on the Alliance Grant, says: “We are deeply grateful to Sartorius for their generosity and vision. Training our graduate and undergraduate students on the highly specialized equipment in the Bioprocessing Automation Lab is critical to the growth of Canada’s biomanufacturing economy, which is currently experiencing a severe talent shortage.”

Samsung Biologics plans to open a regional office in Tokyo

Samsung Biologics a global contract development and manufacturing organization (CDMO), announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16. During the main track presentation, Samsung Biologics’ CEO and President John Rim said, “Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and launch of antibody-drug conjugate (ADC) services.” He added, “We’ll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products.” Key business updates include: ADC services: To address the increasing demand for ADC-based therapeutics, Samsung Biologics has commenced ADC services at its new dedicated facility. Building on the company’s expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics’ service scope spans late stage discovery, development, and conjugation. Samsung Biologics recently expanded its collaboration with LigaChem Biosciences to support a series of their ADC programs at Samsung Biologics’ new dedicated ADC facility. Opening of Japan office: To better support Samsung Biologics’ expanding global client base, the company announced plans to open a regional office in Tokyo this year. The local presence will boost Samsung Biologics ability to support and grow its increasing partnerships in Japan. Expanded Drug Product (DP) services: As part of continued efforts to expand service offerings, Samsung Biologics is investing in pre-filled syringe (PFS) capabilities. The company’s fully automated PFS DP line will be CGMP ready by 2027.

Aragen secures $100 Mn investment from Quadria Capital

Aragen, a globally renowned Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has secured a $100 Mn investment from Quadria Capital, an Asia healthcare-focused Private Equity fund. The investment will result in Quadria acquiring a minority stake in Aragen, at an approximate valuation of USD 1.4 bn, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors. This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe. With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen. This partnership further solidifies Aragen’s reputation for delivering high-quality “concept to clinic” and “concept to commercial” services to its global customer base comprising all sectors of health – Human, Animal and Plant. The announcement comes ahead of JPM Week 2025, where Aragen is expected to secure additional outsourcing partnerships. “We are delighted to welcome Quadria to Aragen. This investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market,” said Manni Kantipudi, CEO, Aragen Life Science. “Our expanded capabilities will allow us to support the rising demand for integrated discovery and manufacturing services, and, most importantly, help our customers accelerate their programs to market faster and more efficiently.” Dr. Amit Varma, Managing Partner and co-Founder of Quadria Capital, said, “The pharmaceutical outsourcing sector presents compelling growth opportunities, especially in the current environment which is driven by global supply chain reorganization. Aragen’s impressive track record, customer-centric approach, and commitment to innovation make it an ideal partner for global pharmaceutical companies. We look forward to partnering with them and supporting their next phase of growth.” This investment marks another milestone in Quadria’s continued focus on high-growth opportunities in the healthcare sector.

FUJIFILM Diosynth Biotechnologies Expands Mammalian Cell Culture Capacity

The Danish life science industry is getting yet another boost as FUJIFILM Diosynth Biotechnologies celebrates its recent production expansion in Denmark. FUJIFILM Diosynth Biotechnologies is a world-leading contract development and manufacturing organization (CDMO) for the biopharmaceutical industry. This first expansion for the site increases capacity from six to twelve bioreactors for mammalian cell culture, making the site the largest end-to-end biopharmaceutical manufacturing site in Europe. A groundbreaking ceremony for the expansion took place in 2020. “Our activities in Hillerød reflect our commitment to being the leading contract manufacturer globally, or a Partner for Life, as we call it, by supporting our clients and their patients worldwide,” says Christian Houborg, site head and senior vice president for FUJIFILM Diosynth Biotechnologies. “This expansion demonstrates our vision to launch strong production capabilities in the global biopharmaceutical industry, ensuring the timely delivery of critical therapies to those in need worldwide,” says Christian. The expansion of the Company’s production in Hillerød underscores that the Danish life science sector is in a very good trajectory, according to Brian Mikkelsen, CEO of Dansk Erhverv. He points out that the industry has been an outstanding Danish success story with massive growth, steadily increasing exports, and several thousand new jobs in recent years. Since 2019, the FUJIFILM Diosynth Biotechnologies site in Hillerød has grown from 750 employees to approximately 1800 today, and approximately 20 percent of them come from abroad, representing more than 70 different nationalities. “One must tip their hat to FUJIFILM Diosynth Biotechnologies and their impressive journey, of which this expansion is the latest evidence. It is a company that contributes both through their production and growth to Danish society. That is something to celebrate,” says Brian Mikkelsen. He points out that the latest expansion from FUJIFILM Diosynth Biotechnologies merely emphasizes that the potential for continued growth in the life science industry is indeed present. “This first expansion of our site in Hillerød sets the stage for future developments, which will also extend to the USA, United Kingdom, and Japan,” said Lars Petersen, president and chief executive officer, FUJIFILM Diosynth Biotechnologies. “By investing in state-of-the-art facilities on both sides of the Atlantic and prioritizing our employees, we are uniquely positioned to meet the needs of our partners and patients.” “This is just the beginning. With our Partners for Life strategy, we are dedicated to fulfilling our promises and ensuring that our global network supports the production of life-changing medicines that improve patients’ lives,” concluded Petersen. “The life science industry has the potential to double exports by 2030, but this requires us to continue supporting the industry with favorable framework conditions. Therefore, I am happy that we have now also received a new life science strategy that improves the framework for Danish production, research, and development,” says Brian Mikkelsen.

United Imaging Announces Major Expansion of U.S. Manufacturing Space

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has signed on for additional production and office space in greater Houston. The new space in Pearland, Texas will more than triple the total size of the company's current manufacturing square footage that's now at their North American headquarters on Kirby Drive. It was only just over four years ago that the company opened that current production facility. United Imaging has been steadily increasing U.S. production since then, with products in all four imaging modalities it currently sells achieving local production in Texas over the last four years. All critical spare parts are already stored in Houston and in stocking locations across the country. "With the steadily spiking demand and manufacturing capacity also has come an increase in hiring" said Jeffrey M. Bundy, PhD, CEO of United Imaging Healthcare North America. Since 2021, U.S. headcount growth has averaged 60% annually. The proximity to Houston's ports provides strategic opportunity the global company has been investing in for years, with increasing operations in South America and across the world. United imaging also announced recently its first product registrations in Canada. It has installations in 75+ countries worldwide since 2011, and earlier this summer announced its 30,000th unit installed globally, which was in the U.S.

XingImaging Opens State-of-the-Art Research Facility

XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven, Connecticut. The facility includes a clinic to recruit and evaluate participants for clinical research studies, cGMP radiochemistry laboratories, 2 PET-CT and 1 SPECT-CT scanners and image analysis capabilities. This development, featuring advanced research imaging technologies such as the United Imaging ultra-high performance NeuroExplorer PET scanner, enables XingImaging to better serve the research community with a strong focus on quality and precision-driven scientific services. "We are proud to open this facility in the City of New Haven, a hub for research and healthcare innovation," said Gilles Tamagnan, CEO of XingImaging. "The new facility represents a significant leap forward in our mission to deliver high-quality imaging solutions and accelerate the development of life-saving treatments. Our commitment to quality is reflected in every aspect of our research, from the radiotracer manufacturing process to the meticulous analysis of clinical imaging data. Our focus on scientific innovation is exemplified by the inclusion of the state-of-the-art NeuroExplorer PET camera." The NeuroExplorer PET camera from United Imaging is the world's first ultra-high-performance brain PET scanner offering unparalleled resolution (1.4 mm FWHM) and sensitivity (46 kcps/MBq) in the study of brain function. This promises to be a true game changer for imaging of neurodegenerative diseases, like Parkinson's & Alzheimer's, and psychiatric diseases enabling high signal to noise imaging even for small brain structures. The integration of the NeuroExplorer PET camera into XingImaging's services further enhances the company's ability to deliver the highest quality science for its research and drug development partners.

Covestro Invests in Major Expansion in Ohio Facility

Covestro invests a low triple-digit million Euro amount to expand its site in Hebron, Ohio, USA. It will construct multiple new production lines and infrastructure to manufacture customized polycarbonate compounds and blends and significantly expand its capacity in the Solutions & Specialties business for the American market. "This investment in our U.S. compounding plant is an important component of our 'Sustainable Growth' strategy. With this expansion, we can meet our customers' growing demand for specialized polycarbonate materials, grow together with our customers, and strengthen our position as a leading provider of polycarbonate materials in North America," says CTO Thorsten Dreier. "The move also aligns with our strategy to produce in the region for the region, to manufacture close to our customers and ensure reliable supply." The capacity expansion is an important step to meet the growing demand for high-quality materials for the automotive, electronics and healthcare industries in North America. "To be successful in these markets, you need the right portfolio, consistent quality, and supply reliability, as well as solution-oriented technical expertise," says Lily Wang, head of the Engineering Plastics Business Entity. "The expanded production capacity for differentiated polycarbonates enables us to better serve our customers' complex needs for high-quality, high-tech materials with individualized properties." Covestro already has an established R&D center in Pittsburgh, and is now doubling down on its U.S.-based compounding capability. In the future, both facilities will work even more closely together to drive the technology transfer from lab to industrial production to support major transformation processes, such as the electrification and automation of mobility, sustainable developments and digitalization. "This investment, which follows our recent announcement of a 40 Million Dollar investment in our R&D capabilities in Pittsburgh, underscores how critical our U.S. sites and the U.S. market are to Covestro's global strategy," says Samir Hifri, chairman and president of Covestro LLC. "The expanded capacity of our polycarbonate compounding capabilities in Ohio will both help us better supply our customers as well as represents a commitment to our employees, the Hebron, Ohio community, and the U.S. market as a whole."